Nitrase Therapeutics

📍 Brisbane, United States🗓 Founded 2018👥 23 employees💰 Last funded 2021
Biotechnology Research🌐 nitrasetx.com
Website LinkedIn
Nitrase Therapeutics is a pioneering biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes that it discovered, to develop a pipeline of therapies against a broad variety of diseases. The medicines that Nitrase Therapeutics is developing will target these enzymes and potentially help slow or halt the progression of a wide variety of diseases in which nitrases and nitro-substrates play a role, including Parkinson’s and cancer. Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinsons Research (MJFF).
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2018
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Nitrase Therapeutics?
Nitrase Therapeutics has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Nitrase Therapeutics last raise funding?
The most recent investment in Nitrase Therapeutics recorded on gritt.io was in 2021.
When was Nitrase Therapeutics founded?
Nitrase Therapeutics was founded in 2018.
What industry is Nitrase Therapeutics in?
Nitrase Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Nitrase Therapeutics based?
Nitrase Therapeutics is headquartered in Brisbane, United States.